Medicinal Products

Dáil Éireann Debate, Thursday - 18 June 2026

• Díospóireachtaí
• Aimsigh díospóireacht
  • Díospóireachtaí na Dála
  • Díospóireachtaí an tSeanaid
  • Díospóireachtaí Coiste
• Aimsigh vótáil
  • Vótálacha na Dála
  • Vótálacha an tSeanaid
  • Vótálacha Coiste
• Ceisteanna Parlaiminte
  • Ceisteanna scríofa
  • Ceisteanna ó bhéal
• Leideanna cuardaigh
• Nuair a bhíonn tionchar tromchúiseach ag aithrisí

Thursday, 18 June 2026

Ceisteanna (486)

Pádraig O'Sullivan

Ceist:

486. Deputy Pádraig O'Sullivan asked the Minister for Health whether the medicine daraxonrasib is available for the treatment of patients with pancreatic cancer in Ireland; whether it is or will be eligible for reimbursement by the HSE; and if she will make a statement on the matter. [46536/26]

Freagraí scríofa

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• An Freagra Roimhe Sin
• An Chéad Fhreagra eile